Standard biotools CEO Michael Egholm sells $5,126 in stock

Published 28/05/2025, 01:36
Standard biotools CEO Michael Egholm sells $5,126 in stock

Michael Egholm, the President and CEO of Standard Biotools Inc. (NASDAQ:LAB), recently sold 5,116 shares of the company’s common stock. The transaction, dated May 22, 2025, amounted to a total of $5,126, with shares sold at a weighted average price of $1.002 each. The stock, currently trading at $1.03, has shown significant volatility this year with a -41% year-to-date return, according to InvestingPro data. The sale was conducted to cover tax obligations arising from the vesting of restricted stock units awarded in March 2025. Following this transaction, Egholm retains direct ownership of 2,746,664 shares in the company. While management has been actively buying back shares, InvestingPro analysis indicates the company faces challenges with rapid cash burn and profitability, though it appears slightly undervalued at current levels. For deeper insights into Standard Biotools’ financial health and valuation, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.

In other recent news, Standard Biotools Inc. reported a net loss for the first quarter of 2025, with earnings per share (EPS) of -$0.07, falling short of the forecasted -$0.06. Revenue also missed expectations, totaling $40.8 million against a projected $45.6 million. The company’s revenue saw a 10% year-over-year decline, significantly impacted by a 16% drop in both consumables and services revenue, though instrument revenue increased by 24%. Despite these challenges, Standard Biotools improved its net loss by 19% year-over-year and reduced its adjusted cash burn by 33%. For the full year of 2025, the company has set its revenue guidance between $165 million and $175 million. Standard Biotools continues to explore strategic mergers and acquisitions as part of its growth strategy. Furthermore, the company introduced new products and noted strong demand for its Hyperion XDI systems. Analyst firms like TD Cowen and Jefferies inquired about the company’s market dynamics, including its partnership with Illumina (NASDAQ:ILMN), which is expected to drive moderate growth in 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.